日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The effect of an intervention to promote isoniazid preventive therapy on leadership and management abilities

一项旨在促进异烟肼预防性治疗的干预措施对领导和管理能力的影响

Christian, C; Kakande, E; Nahurira, V; Balzer, L B; Owaraganise, A; Nugent, J R; DiIeso, W; Rast, D; Kabami, J; Peretz, J J; Camlin, C S; Shade, S B; Kamya, M R; Havlir, D V; Chamie, G

A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL

一项针对乌干达HIV血清阳性、合并肺结核且CD4⁺ T细胞计数≥350个/μL的成年患者的随机试验,研究了间断性抗逆转录病毒疗法的疗效。

Nanteza, M W; Mayanja-Kizza, H; Charlebois, E; Srikantiah, P; Lin, R; Mupere, E; Mugyenyi, P; Boom, W H; Mugerwa, R D; Havlir, D V; Whalen, C C

HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function.

HIV 特异性 CD8(+) T 细胞产生抗病毒细胞因子,但细胞溶解功能受损

Appay V, Nixon D F, Donahoe S M, Gillespie G M, Dong T, King A, Ogg G S, Spiegel H M, Conlon C, Spina C A, Havlir D V, Richman D D, Waters A, Easterbrook P, McMichael A J, Rowland-Jones S L

Viral dynamics of acute HIV-1 infection

急性HIV-1感染的病毒动力学

Little, S J; McLean, A R; Spina, C A; Richman, D D; Havlir, D V

Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy

强效抗逆转录病毒疗法一年后,血液和淋巴结中人类免疫缺陷病毒的复制和基因型耐药性

Günthard, H F; Wong, J K; Ignacio, C C; Guatelli, J C; Riggs, N L; Havlir, D V; Richman, D D